Video

When Should Patients Switch from Statins to PCSK9 Inhibitors?

Author(s):

Lauren Santye, Assistant Editor

Mark Tesell, PharmD, BCPS, clinical consultant pharmacist at UMass Medical School, discusses the treatment switch from statins to PCSK9 inhibitors in patients with high cholesterol.

Mark Tesell, PharmD, BCPS, clinical consultant pharmacist at UMass Medical School, discusses the treatment switch from statins to PCSK9 inhibitors in patients with high cholesterol.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Monoclonal antibodies are used to treat lung cancer. They are created in a lab and designed to target specific proteins on cancer cells, stopping them from growing and dividing.
Gene therapy in lung cancer (LC) - isometric view 3d illustration
Related Content
Neuromuscular disorders neon glow nervous system visualizing diseases like ALS myasthenia gravis being treated advanced therapies under Neurology
September 9th 2025

Cemdisiran Monotherapy Improves Activities of Daily Living in Myasthenia Gravis

Luke Halpern, Assistant Editor
Pharmacy Focus: Role of Pharmacists in Proper Inhaler Usage
September 9th 2025

Pharmacy Focus: Role of Pharmacists in Proper Inhaler Usage

Jennifer Griffin, PharmD, MS Luke Halpern, Assistant Editor
Motor neuron connecting to muscle fiber, 3D illustration
September 9th 2025

Study: Apitegromab Meaningfully Improves Motor Function in Spinal Muscular Atrophy

Luke Halpern, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
September 9th 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Skin disorder, pepper appearance from scleroderma, autoimmune disease male hand Skin disorder pepper appearance from vitiligo,scleroderma raynaud, medical concept autoimmune disease.
September 9th 2025

Patients With Systemic Sclerosis Face Decreased HDL-C, Increased Lipoprotein(a)

Luke Halpern, Assistant Editor
Op-Ed: Why Banning PBM-Owned Pharmacies Risks Patient Care
September 9th 2025

Op-Ed: Why Banning PBM-Owned Pharmacies Risks Patient Care

Ben Heiser, PharmD
© 2025 MJH Life Sciences

All rights reserved.